From
To
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals are ahead.
GoodRx reveals that while most women spend less than $50 a month on menopause-related treatments, cost remains a major barrier, leading some to delay care or forgo treatment altogether.
(The Center Square) – More than two years after the pandemic ended, New Hampshire lawmakers are pushing a controversial plan that would authorize pharmacists to dispense the drug ivermectin to treat COVID-19 without a prescription.
In an effort to curb the growing abuse of prescription medications and over-the-counter drugs, an "unwanted medical collection" event will be …